Results 1 to 10 of about 8,495 (251)
Frontiers in Cardiovascular Medicine, 2023 BackgroundAntiarrhythmic drugs (AADs) are frequently prescribed following catheter ablation (CA) for atrial fibrillation (AF). However, to date, there is a lack of large-scale, multicenter controlled studies that have confirmed the efficacy of AADs in ...
Gang Chen +4 more
doaj +1 more source
Безопасность и риск фармакотерапии, 2020 Despite all the achievements of modern medicine, heart failure remains one of the most prevalent, severe and prognostically unfavorable conditions that requires close attention of the medical community. The diversity of the clinical picture and the large
O. D. Ostroumova, I. V. Goloborodova
doaj +1 more source
Frontiers in Pharmacology, 2018 Background: Atrial fibrillation (AF) is a significant cause of morbidity and mortality with foreseeably increasing prevalence. While large animal models of the disease are well established but resource intensive, transgenic AF mouse models are not yet ...
Frank T. Stümpel +6 more
doaj +1 more source
Testing of newly synthesized propafenone derivatives antiarrhythmic activity in aconitic model of cardiac arrhythmia in rats [PDF]
Veterinarski Glasnik, 2014 By applying of aconitic test in in vivo experiments in rats under deep anesthesia, there was investigated the antiarrhythmic potential of newly synthetized fluorinated derivatives of propafenone.
Ivković Branka +6 more
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2017 Atrial fibrillation (AF), being both a cause and a consequence of chronic heart failure (CHF), occurs with it significantly more often than in the general population.
Yu. А. Bunin, S. V. Miklishanskaya
doaj +1 more source
Class III Antiarrhythmics and Periprocedural Torsades de Pointes
JACC: Case Reports, 2023 This case series describes 2 women on prolonged therapy with class III antiarrhythmics who developed torsades de pointes polymorphic ventricular tachycardia in the setting of catheter ablation for atrial fibrillation as a result of QTc prolonging factors.
Cristina M. Font, MD +1 more
doaj +1 more source
BMC Cardiovascular Disorders, 2022 Background Neuropsychiatric side effects of cardiac drugs such as nervousness, mood swings and agitation may be misinterpreted as symptoms of anxiety.
Camilla Rotvig +10 more
doaj +1 more source
Медицинский совет, 2021 The article provides a scientific review based on the proceedings of the 2020 American Heart Association consensus on drugs that may cause arrhythmias on a risk-sensitive basis and a guidance on strategies for monitoring, prevention methods and ...
M. V. Leonova
doaj +1 more source
Atrial Flutter in a Newborn: a Case Report
Journal of Cardiovascular Emergencies, 2020 Introduction: The incidence of cardiac arrhythmia is approximately 1% in the neonatal period and 1–3% in late pregnancy. Atrial flutter (AF), a rhythm disorder based on the mechanism of reentry, represents approximately 32% of all neonatal cardiac ...
Cerghit Andreea Paler +6 more
doaj +1 more source
Successful management of massive lamotrigine extended‐release intoxication in a dog
Clinical Case Reports, 2021 A 3‐year‐old spayed female Siberian Husky presented for evaluation following ingestion of approximately 429 mg/kg of lamotrigine extended‐release. She demonstrated severe neurologic and cardiac signs and was treated with lipid emulsion, anticonvulsants ...
Alexis S. McLaine +3 more
doaj +1 more source